Estramustine

TargetMol
Product Code: TAR-T20681
Supplier: TargetMol
CodeSizePrice
TAR-T20681-1mg1mg£189.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20681-2mg2mg£260.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20681-5mg5mg£340.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20681-1mL1 mL * 10 mM (in DMSO)£402.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20681-10mg10mg£511.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20681-25mg25mg£782.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20681-50mg50mg£1,026.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20681-100mg100mg£1,380.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20681-500mg500mg£2,705.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Estramustine is a nitrogen mustard linked to estradiol, usually as phosphate. Estramustine has been used to treat prostatic neoplasms; also has radiation protective properties. Estramustine is selectively taken up by prostate cells and exerts antineoplastic effects by interfering with microtubule of dynamics and by reducing plasma levels of testosterone.
CAS:
2998-57-4
Formula:
C23H31Cl2NO3
Molecular Weight:
440.4
Pathway:
Cytoskeletal Signaling
Purity:
0.9925
SMILES:
C[C@@]12[C@@H](O)CC[C@@]1([H])[C@]3([H])CCC4=C(C=CC(OC(N(CCCl)CCCl)=O)=C4)[C@@]3([H])CC2
Target:
Microtubule Associated

References

1. Perry CM, McTavish D. Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging. 1995 Jul;7(1):49-74. 2. Zhang C, Jing T, Wang F, Gao X, Xu C, Sun Y. Chemotherapy plus estramustine for management of castration-resistant prostate cancer: meta-analysis of randomized controlled trials. Actas Urol Esp. 2014 Apr;38(3):184-91. doi: 10.1016/j.acuro.2013.07.010. Epub 2014 Feb 5. English, Spanish. PubMed PMID: 24507454. 3. Nakai Y, Nishimura K, Nakayama M, Uemura M, Takayama H, Nonomura N, Tsujimura A; Osaka CRPC Clinical Study Collaboration. Weekly, low-dose docetaxel combined with estramustine for Japanese castration-resistant prostate cancer: its efficacy and safety profile compared with tri-weekly standard-dose treatment. Int J Clin Oncol. 2014 Feb;19(1):165-72. doi: 10.1007/s10147-013-0536-7. Epub 2013 Mar 1. PubMed PMID: 23456140. 4. Qin Z, Li X, Zhang J, Tang J, Han P, Xu Z, Yu Y, Yang C, Wang C, Xu T, Xu Z, Zou Q. Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2016 Sep;95(39):e4801. doi: 10.1097/MD.0000000000004801. Review. PubMed PMID: 27684806; PubMed Central PMCID: PMC5265899.